Patients Exploring mixed episodes in bipolar I disorder: When mania a... One of the most misunderstood and often overlooked aspects of BD-I is the occurrence of mixed episodes.
Patients World Bipolar Day: Recognising bipolar I disorder and addres... BD-I is a brain-based condition that affects mood and energy regulation to an extent that disrupts daily life.
R&D Ending trial-and-error: How psychedelics and precision medic... The next phase of psychiatry must go toward treatments that are not only novel, but practical, personalised, and accessible.
News Precision psychiatry push starts in Europe As geopolitical tensions ratchet up around the world, an initiative has been launched to drive improvements in diagnostic accuracy and precision care.
News Alto raises $120m for resistant depression programme Alto Neuroscience has raised $120m that will fund pivotal trials of its recently acquired candidate for treatment-resistant depression.
Patients The critical role pharmacists play in continuity of care for... One recommended approach to enhancing continuity in BD-I treatment is to deploy coordinated care teams.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
